Compugen (NASDAQ: CGEN) is one of 199 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Compugen to related businesses based on the strength of its earnings, dividends, profitability, risk, valuation, analyst recommendations and institutional ownership.
This table compares Compugen and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Compugen and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
Compugen’s rivals have higher revenue, but lower earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and recommmendations for Compugen and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Compugen presently has a consensus price target of $14.00, indicating a potential upside of 374.58%. As a group, “Biotechnology & Medical Research” companies have a potential downside of 4.39%. Given Compugen’s stronger consensus rating and higher possible upside, equities analysts clearly believe Compugen is more favorable than its rivals.
Insider & Institutional Ownership
17.5% of Compugen shares are held by institutional investors. Comparatively, 46.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Compugen has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Compugen’s rivals have a beta of 1.62, meaning that their average share price is 62% more volatile than the S&P 500.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
What are top analysts saying about Compugen Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Compugen Ltd. and related companies.